Connect Biopharma Holdings Ltd ADR (CNTB)

$0.63 +0.06 (10.21%)
Market Cap 31.62M
Revenue (ttm) 0.00
Net Income (ttm) -59.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 316,600
Avg Vol 41,426
Day's Range N/A - N/A
Shares Out 55.25M
Stochastic %K 27%
Beta -0.21
Analysts Strong Sell
Price Target $7.00

Latest News on CNTB

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Apr 1, 2025, 9:00 AM EDT - 1 day ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 4:05 PM EDT - 2 days ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 31, 2025, 9:00 AM EDT - 2 days ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 28, 2025, 4:05 PM EDT - 5 days ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Present at Two Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 4 weeks ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Attovia Therapeutics Appoints Chief Financial Officer

Oct 15, 2024, 7:30 AM EDT - 6 months ago

Attovia Therapeutics Appoints Chief Financial Officer

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 9, 2024, 3:55 PM EDT - 6 months ago

CNTB Stock Dips Amid Biotech Sector Volatility

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Oct 2, 2024, 4:14 PM EDT - 6 months ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Sep 5, 2024, 4:05 PM EDT - 7 months ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jul 1, 2024, 8:00 AM EDT - 9 months ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 6:03 PM EDT - 10 months ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Jun 12, 2024, 4:15 PM EDT - 10 months ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 22, 2024, 4:05 PM EDT - 11 months ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 11 months ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 12, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Dec 11, 2023, 4:05 PM EST - 1 year ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:03 AM EST - 1 year ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 21, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Nov 20, 2023, 4:41 PM EST - 1 year ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 4:15 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Sep 12, 2023, 6:00 AM EDT - 1 year ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Participate in Upcoming September Investor Conferences

Aug 24, 2023, 6:21 PM EDT - 1 year ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 10, 2023, 8:00 AM EDT - 1 year ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jul 5, 2023, 4:05 PM EDT - 1 year ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Jun 1, 2023, 4:05 PM EDT - 1 year ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Mar 18, 2023, 2:40 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma stock up more than 40% after trial data

Mar 17, 2023, 4:38 PM EDT - 2 years ago

Connect Biopharma stock up more than 40% after trial data

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Mar 17, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Mar 6, 2023, 8:15 AM EST - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Feb 6, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Connect Biopharma Provides Business and Clinical Development Program Update

Dec 30, 2022, 7:30 AM EST - 2 years ago

Connect Biopharma Provides Business and Clinical Development Program Update

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Dec 19, 2022, 8:00 AM EST - 2 years ago

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

Oct 27, 2022, 4:05 PM EDT - 2 years ago

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Oct 4, 2022, 8:56 AM EDT - 2 years ago

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Oct 4, 2022, 7:00 AM EDT - 2 years ago

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Oct 3, 2022, 4:10 PM EDT - 2 years ago

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Is A Sleeper Heading Into October Data Readout

Sep 26, 2022, 12:13 AM EDT - 2 years ago

Connect Biopharma Is A Sleeper Heading Into October Data Readout

Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript

Sep 13, 2022, 8:51 PM EDT - 2 years ago

Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

Sep 13, 2022, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Sep 1, 2022, 8:00 AM EDT - 2 years ago

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

Aug 30, 2022, 8:00 AM EDT - 2 years ago

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

Jul 11, 2022, 4:05 PM EDT - 2 years ago

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

Connect Biopharma to Participate at the Jefferies Healthcare Conference

Jun 2, 2022, 4:05 PM EDT - 3 years ago

Connect Biopharma to Participate at the Jefferies Healthcare Conference

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

May 17, 2022, 4:05 PM EDT - 3 years ago

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

May 4, 2022, 7:54 AM EDT - 3 years ago

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

May 3, 2022, 4:05 PM EDT - 3 years ago

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis